- Home
- SEZL vs MESO Comparison
SEZL vs MESO Comparison
Compare SEZL & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SEZL | MESO |
|---|---|---|
| Founded | 2016 | 2004 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Diversified Financial Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 1.8B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | SEZL | MESO |
|---|---|---|
| Price | $66.76 | $17.79 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 2 |
| Target Price | ★ $113.75 | $24.00 |
| AVG Volume (30 Days) | ★ 966.4K | 211.8K |
| Earning Date | 11-05-2025 | 08-28-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 104.61 | N/A |
| EPS | ★ 3.24 | N/A |
| Revenue | ★ $418,632,890.00 | $17,198,000.00 |
| Revenue This Year | $68.97 | $465.44 |
| Revenue Next Year | $26.02 | $75.37 |
| P/E Ratio | $21.70 | ★ N/A |
| Revenue Growth | 88.74 | ★ 191.39 |
| 52 Week Low | $24.86 | $9.61 |
| 52 Week High | $186.74 | $22.00 |
Technical Indicators
Market Signals| Indicator | SEZL | MESO |
|---|---|---|
| Relative Strength Index (RSI) | 53.03 | 56.73 |
| Support Level | $66.72 | $16.43 |
| Resistance Level | $76.39 | $17.65 |
| Average True Range (ATR) | 4.18 | 0.59 |
| MACD | 1.61 | 0.16 |
| Stochastic Oscillator | 60.21 | 56.31 |
Price Performance
Historical ComparisonAbout SEZL Sezzle Inc.
Sezzle Inc is a financing institution that offers technology-driven payment platform. It allows customers to split their purchase into four installments and pay over 6 weeks with only the first payment due at the time of purchase. Companies operations comprise one reportable segment, the majority of which derives revenue from payment processing platform in North America.
About MESO Mesoblast Limited
Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.